A practical reference on GHRH analog: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-11-23 and is reviewed periodically as new material appears.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from truncated or oxidized forms. Mass spectrometry confirms the expected molecular weight, and peptide mapping after enzymatic digestion verifies the amino acid sequence. Water content is measured because residual moisture affects stability, and tests for aggregates or particulates are standard for injectable peptides. Circular dichroism can indicate whether the molecule has adopted an unexpected secondary structure in solution.
Research supply is often accompanied by a certificate of analysis listing chromatographic purity, mass confirmation, and storage conditions. Laboratories compare that document with an independent test when material is intended for bench work, since certificates describe a batch rather than an individual vial. Published studies usually state the source and purity of the peptide because small differences in purity can shift measured activity. Full analytical validation is rarely reported, which leaves batch-to-batch comparability an open question.
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | 2 to 8 °C | Refrigerated, protected from light |
| Appearance | White to off-white powder | Lyophilized cake in a single-use vial |
| Solubility | Soluble in water | Yields a clear solution after reconstitution |
| Identity method | Electrospray mass spectrometry | Confirms the expected molecular mass |
| Purity method | Reversed-phase HPLC | Reports main peak against related substances |
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
=== Clinical applications === Thymosin β4 has been tested in multicenter trials sponsored jointly by RegeneRx Biopharmaceuticals Inc (Rockville, MD, USA) and Sigma Tau (Pomezia, Italy) in the United States and Europe in patients with bed sores, ulcers caused by venostasis, and Epidermolysis bullosa simplex and was found to accelerate bed sore and stasis ulcer repair by one month. It has also been tested in patients with chronic neurotrophic corneal epithelial defects and found to promote repair. Thymosin β15 : Levels of human thymosin β15 in urine have shown promise as a diagnostic marker for prostate cancer which is sensitive to potential aggressiveness of the tumour
Sick animals often seek out and eat plants containing compounds like tannins and alkaloids to help purge parasites—a behavior observed by scientists and sometimes cited by indigenous healers as the source of their knowledge.
The company was a substantial food manufacturer, with factories at Cadby Hall in Hammersmith, and from 1921 at Greenford, producing bread, cakes, pies, tea, coffee and ice cream. Lyons branded cakes included treacle tarts, Lyons Bakewell tart, Lyons Battenberg, and Lyons trifle sponges. To the public, J. Lyons & Co. were best known for their chain of teashops which opened from 1894 and finally closed in 1981, and for the Lyons Corner Houses in the West End of London. The teashops provided for tea and coffee, with hot dishes and sweets, cold dishes and sweets, and buns, cakes and rolls. Lyons' teashops were slightly more up market than their ABC (Aerated Bread Company) competitors. They were notable for their interior design, from the 1920s Oliver P. Bernard being consultant artistic director. Until the 1940s they had a certain working-class chic, but by the 1950s and 1960s they were quick stops for busy shoppers where one could drink a cup of tea and eat a snack or an inexpensive meal. The teashops always had a bakery counter at the front, and their signs, Art Nouveau gold lettering on white, were a familiar landmark. Before the Second World War service was to the table by uniformed waitresses, known as 'Nippies'; after the war the teashops converted to cafeteria service.
=== Legacy and claims of responsibility === Multiple claims of responsibility have continued to be put forward years after the recovery of the pumpkin. In 1999, editor-in-chief of the school paper Farhad Manjoo received an anonymous tip which potentially explained how the prank was carried out, involving a climb up the spire of the tower and the use of duct tape. The May 2000 Graduation issue of the Cornell Daily Sun stated that the prank was carried out by one Cornell student ringleader and two other Ithacan accomplices. In the Cornell Chimes Newsletter, it was stated that a student from the University of Montana, "Rob", confessed to former Head Chimesmaster Courtney Kimball that they had placed the pumpkin; Atlas Obscura deemed this inauthentic, though Cornell historian Ryan Earle stated that this was "the best source for how it happened." One rumor also claimed that the prankster's identity was passed down through each university archivist. In 2017, 20 years following the placement of the first pumpkin atop the tower, Manjoo, then reporter at The New York Times, called the event "the greatest prank in Cornell history" and that there was "no downside" in the pranksters coming forward as "all of that has passed now. Now they're just legends." Evan Fay Earle, the university archivist in 2017, stated that the pumpkin "continue[d] to generate interest at Cornell and [in] the community". The website about the pumpkin was partially brought back online for the anniversary.
==== MeSH D13.570.230 – deoxyribonucleosides ==== MeSH D13.570.230.229 – deoxyadenosines MeSH D13.570.230.229.075 – cladribine MeSH D13.570.230.229.105 – dideoxyadenosine MeSH D13.570.230.229.650 – puromycin aminonucleoside MeSH D13.570.230.329 – deoxycytidine MeSH D13.570.230.329.100 – bromodeoxycytidine MeSH D13.570.230.329.950 – zalcitabine MeSH D13.570.230.329.950.500 – lamivudine MeSH D13.570.230.360 – deoxyguanosine MeSH D13.570.230.430 – deoxyuridine MeSH D13.570.230.430.196 – bromodeoxyuridine MeSH D13.570.230.430.432 – floxuridine MeSH D13.570.230.430.609 – idoxuridine MeSH D13.570.230.500 – dideoxynucleosides MeSH D13.570.230.500.090 – didanosine MeSH D13.570.230.500.105 – dideoxyadenosine MeSH D13.570.230.500.850 – stavudine MeSH D13.570.230.500.925 – zalcitabine MeSH D13.570.230.500.925.500 – lamivudine MeSH D13.570.230.500.950 – zidovudine MeSH D13.570.230.677 – pentostatin MeSH D13.570.230.855 – thymidine MeSH D13.570.230.855.875 – stavudine MeSH D13.570.230.855.900 – trifluridine MeSH D13.570.230.855.950 – zidovudine
Sources: en.wikipedia.org
zinc finger (ZF) A supersecondary polypeptide structural motif and DNA-binding domain occurring in many DNA-binding proteins, characterized by a series of non-adjacent amino acid residues which fold into a three-dimensional arrangement capable of coordinating one or more zinc ions (Zn2+) between them, thus stabilizing the fold into a definite structure that can interact specifically with other biomolecules such as nucleic acids or other polypeptides. There are many distinct classes of zinc fingers using different ligands and spatial arrangements to achieve coordination; in perhaps the most common variant, a short alpha helix is oriented antiparallel to a β sheet, with two histidine residues in the former and two cysteines in the latter forming the coordination complex. Zinc fingers bind DNA as the primary functional domain of many transcription factors.
=== 2020: US Open final === Zverev began his 2020 season at the inaugural ATP Cup. Germany was in Group F alongside Australia, Greece, and Canada. Against Australia, he lost to Alex de Minaur in three sets. Australia won the tie over Germany 3–0. Against Greece, he was defeated by Stefanos Tsitsipas. Germany won the tie over Greece 2–1. Against Canada, he was beaten by Denis Shapovalov. Canada won the tie over Germany 2–1. Germany ended third in Group F. Seeded seventh at the Australian Open, he first defeated Marco Cecchinato in the first round in straight sets. After the match, he pledged to donate all his prize money from the tournament to relief efforts for the ongoing bushfires if he won the title, a total of A$4.12 million. He then defeated Egor Gerasimov, Fernando Verdasco, and 17th seed Andrey Rublev to reach the quarterfinals without dropping a set. He defeated 15th seed and 2014 champion, Stan Wawrinka, in the quarterfinals in four sets to reach his first major singles semifinal. He fell in his semifinal match to fifth seed, Dominic Thiem, in four sets. During the week of 24 February, Zverev played at the Mexican Open. Seeded second, he was upset in his second-round match by qualifier Tommy Paul. Starting from 12 March through early August, the ATP suspended tournament play due to the COVID-19 pandemic. At the US Open, Zverev was seeded fifth. He defeated Kevin Anderson in four sets, then beat 19-year old Brandon Nakashima in four sets. In the third round, he beat Adrian Mannarino in four sets before beating Alejandro Davidovich Fokina in straight sets.
By the end of the 19th century, Cossack communities enjoyed a privileged tax-free status in the Russian Empire, although they had a 20-year military service commitment (reduced to 18 years from 1909). They were on active duty for five years, but could fulfill their remaining obligation with the reserves. At the beginning of the 20th century, the Russian Cossacks numbered 4.5 million. They were organized as independent regional hosts, each comprising a number of regiments. The need for the government to call up Cossack men to serve either with the Army or a mounted police force caused many social and economic problems, which compounded by the growing impoverishment the communities of the Hosts. Treated as a separate and elite community by the Tsar, the Cossacks rewarded his government with strong loyalty. His administration frequently used Cossack units to suppress domestic disorder, especially during the Russian Revolution of 1905. The Imperial Government depended heavily on the perceived reliability of the Cossacks. By the early 20th century, their decentralized communities and semi-feudal military service were coming to be seen as obsolete. The Russian Army Command, which had worked to professionalize its forces, considered the Cossacks less well disciplined, trained, and mounted than the hussars, dragoons, and lancers of the regular cavalry. The Cossack qualities of initiative and rough-riding skills were not always fully appreciated. As a result, Cossack units were frequently broken up into small detachments for use as scouts, messengers, or picturesque escorts.
Glutathione S-transferase theta-2 is an enzyme that in humans is encoded by the GSTT2 gene. Glutathione S-transferase (GSTs) theta 2 (GSTT2) is a member of a superfamily of proteins that catalyze the conjugation of reduced glutathione to a variety of electrophilic and hydrophobic compounds. Human GSTs can be divided into five main classes: Alpha, Mu, Pi, Theta, and Zeta. The theta class members GSTT1 and GSTT2 share 55% amino acid sequence identity and both are thought to have an important role in human carcinogenesis. The theta genes have a similar structure, being composed of five exons with identical exon/intron boundaries.
== Success rate == Candidates for a new drug to treat a disease might, theoretically, include from 5,000 to 10,000 chemical compounds. On average about 250 of these show sufficient promise for further evaluation using laboratory tests, mice and other test animals. Typically, about ten of these qualify for tests on humans. A study conducted by the Tufts Center for the Study of Drug Development covering the 1980s and 1990s found that only 21.5 percent of drugs that started Phase I trials were eventually approved for marketing. In the time period of 2006 to 2015, the success rate was 9.6%. The high failure rates associated with pharmaceutical development are referred to as the "attrition rate" problem. Careful decision making during drug development is essential to avoid costly failures. In many cases, intelligent programme and clinical trial design can prevent false negative results. Well-designed, dose-finding studies and comparisons against both a placebo and a gold-standard treatment arm play a major role in achieving reliable data.
Sources: en.wikipedia.org
The highest-volume chemicals made by biocatalysis are bio-ethanol (70 million metric tons), high-fructose corn syrup (2 million metric tons), acrylamide, 6-aminopenicillanic acid (APA), L-lysine and other amino acids, citric acid and niacinamide (all more than 10,000 metric tons). Biosynthesis, the conversion of organic materials into fine chemicals by microorganisms, is used for the production of both small molecules (using enzymes in whole cell systems) and less complex, non-glycosylated big molecules, including peptides and simpler proteins. The technology has been used for 10,000 years to produce food products, like alcoholic beverages, cheese, yogurt, and vinegar. In contrast to biocatalysis, a biosynthetic process does not depend on chemicals as starting materials, but only on cheap natural feedstock, such as glucose, to serve as nutrient for the cells. The enzyme systems triggered in the particular microorganism strain lead to the excretion of the desired product into the medium, or, in the case of HMW peptides and proteins, to the accumulation within so-called inclusion bodies in the cells. The key elements of fermentation development are strain selection and optimization, as well as media and process development. Dedicated plants are used for large-scale industrial production. As the volume productivity is low, the bioreactors, called fermenters, are large, with volumes that can exceed 250 m3 (8,828.67 cubic feet). Product isolation was previously based on large-volume extraction of the medium containing the product.
=== Available forms === Buprenorphine/naloxone is available in sublingual formulations (that is, products that are dissolved under the tongue). It is also available through monthly injection by healthcare provider. There is no evidence that the tablet formulation is easier to divert and use in ways other than intended by the prescriber compared to the film formulation, or that the tablet formulation has a higher risk for accidental ingestion by children. There are various pharmacokinetic differences between sublingual formulations.
This was Merck's first use of the designation and the reduction in regulatory risk was one of the reasons management was willing to put company resources into development. In 2013, the United States Adopted Name (USAN) name was changed from lambrolizumab to pembrolizumab. In that year clinical trial results in advanced melanoma were published in The New England Journal of Medicine. This was part of the large phase I NCT01295827 trial. In September 2014, the US Food and Drug Administration (FDA) approved pembrolizumab under the Fast Track Development Program. It is approved for use following treatment with ipilimumab, or after treatment with ipilimumab and a BRAF inhibitor in advanced melanoma patients who carry a BRAF mutation. As of 2015, the only PD-1/PD-L1 targeting drugs on the market are pembrolizumab and nivolumab. By April 2016, Merck applied for approval to market the drug in Japan and signed an agreement with Taiho Pharmaceutical to co-promote it there. In July 2015, pembrolizumab received marketing approval in the European Union. In October 2015, the US FDA approved pembrolizumab for the treatment of metastatic non-small cell lung cancer (NSCLC) in people whose tumors express PD-L1 and who have failed treatment with other chemotherapeutic agents. In July 2016, the US FDA accepted for priority review an application for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) after a platinum-based chemotherapy.
BioShock is a first-person shooter with role-playing customization and stealth elements, and is similar to System Shock 2. The player takes the role of silent protagonist Jack as he is guided through Rapture towards various objectives. The player battles enemies using a combination of traditional weaponry and magic-like plasmids. Aside from the wrench, a melee weapon, players can upgrade their weapons through upgrade stations scattered across the environment; these upgrades modify weapons with added range, lessened recoil, or similar improvements. Weapons can also be equipped with different ammo types to increase effectiveness against varied targets. Plasmids confer superpowers such as casting fire or electric attacks, and in some cases can be used to access new areas—for example, melting ice blocking a path, or tripping the electric lock to open a door. Using plasmids requires EVE—the equivalent of mana—which can be replenished with EVE hypos or certain consumable food and drink. The player has a health meter that decreases when they take damage. The player can restore their health with food or medical packs found throughout Rapture. If the player's health is reduced to zero, they will respawn at a nearby Vita-Chamber, a device that functions as a checkpoint system. A patch for the game allows the Vita-Chambers to be turned off, requiring players to restart a saved game if the character dies.
Many earthworms can eject coelomic fluid through pores in the back in response to stress. The Australian Didymogaster sylvaticus (known as the "blue squirter earthworm") can squirt fluid as high as 30 cm (12 in).
Sources: en.wikipedia.org
Lyophilized material is typically kept refrigerated and away from light in the sealed vial provided. Dissolved material is generally used within a limited period rather than stored long term.
Mass spectrometry gives the molecular weight, and mapping after digestion gives sequence coverage. Reversed-phase chromatography then supplies a purity profile.
Different groups report purity with different methods and thresholds, and full validation data are seldom published. Direct comparison of activity across batches therefore stays uncertain.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.